San Francisco start-up Verge , a Y Combinator graduate, has raised $32 million in a series A funding led by DFJ. tech incubator Y Combinator. ALS is developing drugs to treat amyotrophic lateral sclerosis ( Verge Genomics ), also known as Draper Fisher Jurvetson disease, by comparing samples of cells from people who have died from the disease with those of healthy brains and also uses mice to study human diseases. Its teams then use machine-learning algorithms to identify the genes triggering ALS. The company is focusing on finding chemical molecules that can be turned into drugs, and aims to expand its research to include Parkinson’s disease.
San Francisco start-up Verge , a Y Combinator graduate, has raised $32 million in a series A funding led by DFJ. ALS is developing drugs to treat amyotrophic lateral sclerosis ( Verge Genomics ), also known as Draper Fisher Jurvetson disease, by comparing samples of cells from people who have died from the disease with those of healthy brains and also uses mice to study human diseases. Its teams then use machine-learning algorithms to identify the genes triggering ALS. The company is focusing on finding chemical molecules that can be turned into drugs, and aims to expand its research to include Parkinson’s disease.